2020 Volume 8 Issue 2 Pages 51-56
Aim: This study aimed to clarify indications under insurance coverage for measuring the serum ratio of soluble fms-like tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF ratio), and to construct a flow diagram for the short-term prediction of preeclampsia (PE) using the sFlt-1/PlGF ratio in women at imminent/basal risk of preeclampsia.
Methods: Indications for measuring the serum sFlt-1/PlGF ratio were selected, and a flow diagram for predicting PE using the ratio in women at imminent/basal risk of PE at 18–36 weeks of gestation was constructed, based on the consensus of 6 experts at the “sFlt-1/PlGF Advisory Web Meeting” held after the PROGNOSIS Asia study.
Results: Based on expert consensus, appropriate perinatal care under close observation is recommended for women at imminent/basal risk of PE who have an sFlt-1/PlGF ratio >38 at recruitment. For women at imminent risk of PE who have an sFlt-1/PlGF ratio ≤38 at recruitment, shortening the interval between maternal check-ups is recommended, along with re-evaluation of the sFlt-1/PlGF ratio 1–4 weeks after initial blood sampling, based on patient/fetal condition.
Conclusions: The indications and screening strategy for PE using the serum sFlt-1/PlGF ratio under insurance coverage in women at imminent/basal risk of PE will help prevent unnecessary hospitalization and intervention, assist in the triage of women at imminent/basal risk of PE, and allow for the provision of appropriate perinatal care under close observation.
